In line with these findings, Cetuximab has shown to inhibit the increased glioma cell invasion after the therapy with DC101, a mAb against VEGFR-2 with a potent antiangiogenic activity (Lamszus et al, 2005). This evidence concerns the gene KDR and glioma.